196 related articles for article (PubMed ID: 36796019)
21. Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship.
Wang L; Zhang Z; Yu D; Yang L; Li L; He Y; Shi J
Bioorg Chem; 2023 Sep; 138():106577. PubMed ID: 37178649
[TBL] [Abstract][Full Text] [Related]
22. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA
Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.
Lee E; Cho H; Lee DK; Ha J; Choi BJ; Jeong JH; Ryu JH; Kang JS; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126415
[TBL] [Abstract][Full Text] [Related]
24. Discovery of Pteridine-7(8
Dou D; Diao Y; Sha W; Su R; Tong L; Li W; Leng L; Xie L; Yu Z; Song H; Shen Z; Zhu L; Zhao Z; Xie H; Chen Z; Li H; Xu Y
J Med Chem; 2022 Feb; 65(3):2694-2709. PubMed ID: 35099969
[TBL] [Abstract][Full Text] [Related]
25. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
[TBL] [Abstract][Full Text] [Related]
26. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blombery P; Thompson ER; Lew TE; Tiong IS; Bennett R; Cheah CY; Lewis KL; Handunnetti SM; Tang CPS; Roberts A; Seymour JF; Tam CS
Blood Adv; 2022 Oct; 6(20):5589-5592. PubMed ID: 35901282
[TBL] [Abstract][Full Text] [Related]
27. Development of BTK inhibitors for the treatment of B-cell malignancies.
Kim HO
Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
[TBL] [Abstract][Full Text] [Related]
28. Pirtobrutinib: First Approval.
Keam SJ
Drugs; 2023 Apr; 83(6):547-553. PubMed ID: 37004673
[TBL] [Abstract][Full Text] [Related]
29. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
30. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.
Huang W; Wang S; Zhang Z; Zhang C; Zeng S; Liang M; Shen Z; Liu X
Bioorg Chem; 2020 Dec; 105():104377. PubMed ID: 33091668
[TBL] [Abstract][Full Text] [Related]
31. Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo.
Song X; Rao H; Guo C; Yang B; Ren Y; Wang M; Li Y; Cao Z; Pei J
Phytomedicine; 2021 Dec; 93():153802. PubMed ID: 34710755
[TBL] [Abstract][Full Text] [Related]
32. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
33. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
Barf T; Covey T; Izumi R; van de Kar B; Gulrajani M; van Lith B; van Hoek M; de Zwart E; Mittag D; Demont D; Verkaik S; Krantz F; Pearson PG; Ulrich R; Kaptein A
J Pharmacol Exp Ther; 2017 Nov; 363(2):240-252. PubMed ID: 28882879
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel BTK PROTACs for B-Cell lymphomas.
Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y
Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879
[TBL] [Abstract][Full Text] [Related]
35. Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Wang S; Mondal S; Zhao C; Berishaj M; Ghanakota P; Batlevi CL; Dogan A; Seshan VE; Abel R; Green MR; Younes A; Wendel HG
JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217352
[TBL] [Abstract][Full Text] [Related]
36. The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives.
Eyre TA; Riches JC
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174062
[TBL] [Abstract][Full Text] [Related]
37. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
Easaw S; Ezzati S; Coombs CC
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):697-704. PubMed ID: 37544810
[TBL] [Abstract][Full Text] [Related]
38. Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors.
Lin TE; Sung LC; Chao MW; Li M; Zheng JH; Sung TY; Hsieh JH; Yang CR; Lee HY; Cho EC; Hsu KC
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):226-235. PubMed ID: 34894949
[TBL] [Abstract][Full Text] [Related]
39. Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies.
Goodstal SM; Lin J; Crandall T; Crowley L; Bender AT; Pereira A; Soloviev M; Wesolowski JS; Iadevaia R; Schelhorn SE; Ross E; Morandi F; Ma J; Clark A
Sci Rep; 2023 Nov; 13(1):20412. PubMed ID: 37989777
[TBL] [Abstract][Full Text] [Related]
40. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]